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Abstract
To date, vaccination is the most cost-effective strategy to combat infectious diseases. Recently, a productivity gap affects
the pharmaceutical industry. The productivity gap describes the situation whereby the invested resources within an
industry do not match the expected product turn-over. While risk profiles (combining research and development timelines
and transition rates) have been published for new chemical entities (NCE), little is documented on vaccine development.
The objective is to calculate risk profiles for vaccines targeting human infectious diseases. A database was actively compiled
to include all vaccine projects in development from 1998 to 2009 in the pre-clinical development phase, clinical trials phase
I, II and III up to Market Registration. The average vaccine, taken from the preclinical phase, requires a development timeline
of 10.71 years and has a market entry probability of 6%. Stratification by disease area reveals pandemic influenza vaccine
targets as lucrative. Furthermore, vaccines targeting acute infectious diseases and prophylactic vaccines have shown to
have a lower risk profile when compared to vaccines targeting chronic infections and therapeutic applications. In
conclusion; these statistics apply to vaccines targeting human infectious diseases. Vaccines targeting cancer, allergy and
autoimmune diseases require further analysis. Additionally, this paper does not address orphan vaccines targeting unmet
medical needs, whether projects are in-licensed or self-originated and firm size and experience. Therefore, it remains to be
investigated how these - and other - variables influence the vaccine risk profile. Although we find huge differences between
the risk profiles for vaccine and NCE; vaccines outperform NCE when it comes to development timelines.
Citation: Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME (2013) Risk in Vaccine Research and Development Quantified. PLoS
ONE 8(3): e57755. doi:10.1371/journal.pone.0057755
Editor: Nikos Vasilakis, University of Texas Medical Branch, United States of America
Received October 16, 2012; Accepted January 29, 2013; Published March 20, 2013
Copyright:  2013 Pronker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research is supported by NGI 2009 Valorisation Award fund. The funders had no role in study design, data collection and analysis, decision to publish
or preparation of the manuscript.
Competing Interests: Esther S. Pronker is completing her PhD program using funds from the Dutch NGI Valorisation award from 2009. A.D.M.E. Osterhaus
wishes to declare, for the avoidance of any misunderstanding on competing interests, that he co-founded and is chief scientific officer of Viroclinics Biosciences
BV a spin out of Erasmus MC. However, for clarification, no materials or support were received from the company, and no agreements were in place concerning
the execution or publication of this work. There are no patents, products in development or marketed products to declare. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: e.s.pronker@gmail.com
Introduction
Human life expectancy has increased due to the implementation
of hygiene, sanitation and vaccination. Immunization strategies -
of which the use of vaccines is the most important - have prevented
more premature deaths, permanent disability, and suffering, in all
regions in the world, than any other medical intervention [1–4].
Vaccines are the most cost-effective strategy with the potential to
prevent - or even cure - acute and chronic infections, allergic
conditions, auto-immune diseases and cancer [5,6]. Prophylactic
and therapeutic vaccination leading to both individual and herd
immunity as well as symptom relief during disease progression
respectively, will continue to be of fundamental value in
maintaining public health in the future [7,8].
Unfortunately, as with the pharmaceutical industry, also the
biotech sector is affected by the so-called productivity gap [9,10].
The productivity gap describes a situation within an industry
whereby the invested resources do not match the expected product
turn-over [9,10]. Developing a human vaccine from the preclinical
phase to registration requires an increasing average investment of
approximately US$ 200 to 900 million [5]. This process is also
known as the value chain; the consecutive development stages a
vaccine or medical compound progresses through to accumulate
value and become established as a safe, effective and qualitative
product. However, merely 22% of the initiatives were forecasted in
1996 to successfully reach the market after 10 years of
development [11,12]. This imbalance is to a large extent caused
by rising cost of research and development (R&D), biological and
technical challenges associated with targeting more complex
diseases, competition with better standards of care, larger scale
of clinical studies to prove safety and efficacy and last but not least
an increasingly stringent regulatory environment [13,14]. From
the perspective of the patient, and in financial terms: the
subsequent attrition rate is substantial and should be improved.
Value chain descriptives - including, but not limited to; phase
duration and transition rates - are important parameters for
investors seeking strategic financial advice. The result of combin-
ing these two dimensions is a relatively accurate physical
indication of the productivity at different development stages.
The current benchmark on methodologies for determining risk
profiles is published by Dimasi et al (2003) [15], and applies to new
chemical entities (NCE). A risk profile combines data on the
average phase duration with probabilities of projects transitioning
between value chain phases. To date, there is limited documen-
tation on vaccine development. Two articles in particular - one
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from 1996 [12], and a more recent publication from 2011 [16] -
focus on value chain descriptives comparing NCE and vaccine
profiles. We intend to take the analysis one step further and
introduce the additional variable of the target infectious agent.
Objectives
The present paper offers an empirical analysis on the value
chain risk profiles for human vaccines in development from 1998
to 2009. We hypothesize that current vaccine risk profiles behave
in a pattern similar to those described for NCEs: since 1983 to
1994 [12] the overall phase duration is postulated to have
lengthened but the market entry probability is expected to remain
relatively constant [17]. Moreover, by stratifying data according to
infectious disease areas, we aim to identify the development stages
during which attrition rates are highest. In the competitive
landscape where resources are limited, the overview allows for
vaccine developers and investors to anticipate common project-
level challenges for the particular disease area.
Study Design
Our methodology and assumptions are based on Struck [12],
and Dimasi [17]. Data is collected on five value chain phases on
the basis of availability, observing human vaccines in development
from 1998 to 2009. The five development phases included in the
analysis; Preclinical (PC), Human Clinical Trials Phase I–III (PI-
III) and Regulatory submission (RS). Discontinued projects (D) are
also included. Where available, data is updated to 2010. An active
research strategy is chosen to develop the proprietary dataset,
cross-referencing various sources including; commercial database
(Medtrack ), governmental sources, company sources open to
the public, official press statements and scientific publications.
Medtrack  is opted due to accessibility, and is compatible to
Pharmaprojects .
Using the commercial database as a starting point, a total of 902
vaccine candidates during any stage of development were included
in the dataset. Data was collected on the 12th of May 2010
showing 1495 entries. By excluding products on the market, in
post-marketing trials, or where no details were found (NA), 902
unique products remain. It was assumed that the database is
current and contains an accurate record of all vaccine projects,
making randomization unnecessary. Consequently the data was
filtered according to specific in- and exclusion criteria (Table 1). By
defining the dataset we assumed that phases do not overlap, and
that each vaccine progresses through the same stages in
chronological order.
Phase duration was determined by the average number of years
a vaccine candidate takes to complete a development phase.
Discontinued projects were not included in this calculation since
the decision can occur at any moment distorting results; 456
vaccine projects remain eligible. For practical reasons we consider
a year to have 360 days.
The second element of the risk profile constitutes the transition
probability, which was determined by applying the formula as
described in [17]. Furthermore, the cumulative transition ratio is
taken to represent the market entry probability. It indicates the
proportion of vaccine candidates that developed successfully from
PC to the highest attainable development phase. All vaccine
projects in the dataset were included in these calculations.
Lastly, data was stratified according to therapeutic area for
investigating this third variable influence on the phase duration
and transition probabilities. Furthermore, within this infectious
disease category, data on vaccines against acute infections, chronic
infections, preventative indications and therapeutic indications are
analyzed separately. Nevertheless, in order to recognize the
significance of the disease area, risk profiles are placed into
context of the disease burden and invested resources. The
estimated patient population is taken to represent the former
aspect, whereas the latter was measured by total sum of the value
of merger and acquisition (M&A) deals. The commercial database
Pharma ETrack  is consulted on financial statistics of M&A. The
sum of M&A activity in US $ Million since 2004 is calculated as an
indication for the amount of resources the biotech industry invests
in the particular disease area. The disease areas covered by the
majority of vaccine projects are presented in this paper.
Results
The filtered dataset contains 605 unique human vaccine
candidates during any stage of development, from 188 individual
firms covering over 60 therapeutic areas. The risk profile for the
average vaccine in development from 1998 to 2009 only partially
behaved as predicted (Figure 1) the timeline has lengthened by
0,71 years, yet the cumulative success rate is lower at an estimated
transition probability of 0,07 (Table 2). On account of the sizeable
standard deviations, we would advocate that risk profile param-
eters delineating the entirety of the dataset should only be
interpreted as an indication for the general development trend of
the vaccine manufacturing industry.
When dividing the data according to the third variable - areas of
therapeutic intervention - 49% of the vaccine pipeline covers 5
conditions. Furthermore, Japanese Encephalitis (JE) vaccine
projects are highlighted due to multiple recent product approvals.
These include; Ixiaro  (Intercell AG, also known as Jeev  and
Jespect , available since 2009 in various countries), and beyond
the scope of the dataset Encevac  (Kaketsuken, in Japan since
Jan 2011) and Imojev  (Sanofi, available in Australia and
Thailand since July 2011). The remaining disease areas are not
represented by a sufficient quantity of vaccine projects to attain
statistically significant comparisons.
By far the most lucrative business opportunity is created by
pandemic influenza. In this saturated environment, efficiency is
the key word if vaccine manufacturers desire to maintain a
competitive advantage. As the current manufacturing capacity for
influenza vaccines is limited at 900 million dosages [18],
innovations are namely pursued in areas including adjuvant
development, delivery system and manufacturing technology [19].
Nevertheless, pandemic influenza vaccine preparedness is a
unique and rare situation that should not be compared to vaccines
targeting other disease areas.
Pandemic influenza preparedness efforts are largely aligned with
World Health Organization’s advice to national governments on
societal, antiviral and vaccine strategies, based on monitoring the
threat-level of emerging potential pandemic influenza viruses [20].
Since purchasing vaccines for immunization campaigns is
coordinated by national governments, they are responsible for
ensuring sufficient access from the early stages of an influenza
pandemic onward. Over the past few decades, several govern-
mental bodies followed the WHO preparedness advice and
proactively sought advanced purchase agreements with vaccine
manufacturers. Such agreements led vaccine manufacturers to
anticipate an increasing demand for influenza vaccines, and as a
result they invested in expanding their manufacturing capacity.
Furthermore, during the 2009 H5N1 influenza pandemic, vaccine
acquisition by individual governments proved to be an inefficient
system, and the European Committee (EC) responded by
establishing a joint procurement initiative for future pandemic
threats in November 2011 [21,22]. Obviously the sustainability of
Vaccine Research and Development Risk Quantified
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Table 1. In- and exclusion criteria for fine-tuning the dataset, inspired by [16].
Inclusion criteria Exclusion criteria
EMPHRA Code J7 = human vaccine product, prophylactic and therapeutic. Vaccine product undergoing post-market clinical trials for
additional indications
Vaccines target human infectious diseases caused by; viral, bacteria, fungi, parasites,
bacterial toxins and unspecified infectious agents.
Vaccines targeting cancer, allergy and auto-immune
indications.
The database entry has descriptive information on the product; sponsor company,
therapeutic area, at least one date indicating the state of the current development phase
The vaccine product cannot be found on at least one other
source.
Except for products in PC or D phases, as these are
underreported
Product is in the following phases according to the database; PCa, PIb, PIIc, PIIId, RSe, Df. Products in the following phases according to the database:
Mg, PMh, NAi, Fj.
Start of PC phase in 1998 Duplicate entries
aPreclinical Phase;
bHuman clinical trials Phase One;
cHuman clinical trials Phase Two;
dHuman clinical trials Phase Three;
eRegulatory submission to allow market entry;
fProjects discontinued for any reason during any stage of the following stages of vaccine development in PC, PI, PII and PIII;
gMarket phase;
hPost-marketing, also known as human clinical trials phase four;
iNo information available;
jFailed or terminated vaccine products. In other words, products that have received regulatory market approval, but have been withdrawn from the market for any
reason.
doi:10.1371/journal.pone.0057755.t001
Figure 1. Vaccine risk profiles for selected disease areas. Risk profiles for the selected disease areas, combining phase duration with the
cumulative transition probabilities as indicated by market entry probabilities. Rank order indicates quantity of projects in data set. Data points are
labelled on the All Data curve; this labelling also applies to the other curves.
doi:10.1371/journal.pone.0057755.g001
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such provisions is largely dependent on the political will and
compliance of individual member states and it probably will be
hard to implement in the current era of ‘post-pandemic fatigue.’
Additionally, JE represents an attractive target for vaccine
developers; with merely 11 firms in our dataset investing in R&D,
over 1 in 10 initiatives successfully attain regulatory submission
phase. The short and steep risk profile presumes half the
candidates from PC progress to subsequent PI trials. Nevertheless,
due to the low number of candidate vaccines in later stages of
development, we believe the timeline is underestimated.
The foremost challenge in vaccine development is reducing the
average transition rate from clinical phase II to III. Between these
value chain phases the risk profile incorporating all data has an
estimated transition probability of 0,21. It represents the highest
attrition rate when compared to the productivity of the other
phases. Both Anthrax and Malaria risk profiles confirm the
bottleneck, as project development activities do not advance
beyond PIII. The phenomenon has been recognized in NCE
development, and we believe the underlying mechanisms and
explanations are also applicable for vaccines [23–25].
A second major obstacle is a successful transition from clinical
phase III to regulatory submission. Such bottlenecks are evident in
Pandemic Influenza, and Hepatitis B vaccine (HBV) risk profiles,
whereby the attrition rate for HBV candidates is calculated at an
astonishing 50%. HIV/AIDS projects are also affected by
significant attrition rates between these stages. Reasons for
submission failures have been described for NCEs, and we assume
similar arguments are relevant [26].
Data was further granulated into vaccines targeting acute versus
chronic indications and prophylactic versus therapeutic applica-
tions (Fig 2). According to the dataset, vaccines targeting acute
infectious diseases, as well as prophylactic vaccines clearly have a
lower risk profile when compared to vaccines targeting chronic
diseases or therapeutic applications.
As a final observation: it is generally assumed that a higher
disease burden - preferably in the industrialized world [27] - is an
incentive to dedicate resources to that particular disease area (Fig 3;
Table 2). As an example of the opposite being the case sometimes:
4% of vaccine development projects target anthrax, while the
infection is highly uncommon and related to biological-warfare
[28].
Conclusion
Risk profiles are important descriptive tools providing indica-
tions on possible future vaccine project outcomes, essential for
strategic decision making. In general, the more recent vaccine
development projects from 1998 to 2009 showed a longer timeline
with a lower probability of market entry than those from 1983 to
1994 [12]. What could partially explain the increased phase length
could be the fact that the ICH-E6 Good Clinical Practice
Figure 2. Vaccine risk profile granulating acute versus chronic infections and prophylactic versus therapeutic vaccines. Risk profiles
for vaccines, granulated to show risk profiles for vaccines targeting acute versus chronic infections and prophylactic versus therapeutic vaccines.
Groups are stratified from 100% of the data from the dataset. Percentage per group included.
doi:10.1371/journal.pone.0057755.g002
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guidelines came into effect after Struck’s publication in 1996,
which has influenced clinical research on a global scale. However,
we feel that the phase lengths calculated are not fully represen-
tative for the actual situation. Certain preliminary R&D activities -
such as in silico lead selection and toxicity screening - taking place
prior to patenting are not represented in the dataset. We believe
that when these procedures are taken into consideration, the
actual development timeline is expected to be even longer still.
Additionally, the lengthening timelines for vaccine development
may be influenced by the fact that the so-called ‘low-hanging
fruits’ has already been picked. Data confirms that the majority of
vaccine R&D projects encompassing incremental innovations
targeting disease areas with known correlates of protection have a
shorter development timeline when compared to more radical
vaccine innovations [29]. Nevertheless, vaccine timelines remain
significantly shorter when compared to NCE development.
Clarifications for the discrepant transition probabilities between
our dataset and previous articles expediently relate to data
collection methodologies. Moreover, stratifying data according to
acute or chronic indications as well as therapeutic or prophylactic
application revealed significant variations in transition success.
This confirms that one risk profile cannot represent the
productivity of the overall vaccine development field, and the
effect of a third confounding variable is essential information.
Essentially, infectious diseases are different from cancer, and
both are fundamentally different from allergy and autoimmune
diseases with respect to the mechanisms of pathogenesis, immunity
as well as the approach and difficulty of vaccine development.
Consequently, vaccine development for infectious diseases, cancer,
and allergy/autoimmunity should be analyzed separately. More-
over, this paper does not address orphan vaccines targeting unmet
medical needs, whether projects are in-licensed or self-originated
and firm size and experience [14,30,31]. Therefore it remains to
be investigated how these other variables influence the vaccine risk
profile.
Vaccine development is a risk intensive exercise and requires
substantial investments. As indicated by the risk profiles: the ratio
of success to failure is in favour of the latter. Both the burden of
disease and the magnitude of invested resources into a project
targeting a specific infectious agent do not correlate with a higher
success rate. Substantially resources are dedicated to HIV/AIDS,
even though within the scope of our dataset there are no
regulatory approved vaccines. It is interesting to note that
preventive vaccine development against JEV - a virus that causes
acute infection - may not be considered such a lucrative target as
the market size is too limited to guarantee a rapid return on
investment. Obviously other criteria are used for vaccine target
selection [32,33]. These high rates of attrition need to be reduced
in order to sustain business case growth [34] and respond
appropriately to public health demands.
Several considerations apply to this study. First, we have
assumed that the database on commercial vaccine development -
on which the dataset is based - keeps an accurate record of all
vaccine development projects currently in any phase of develop-
ment. The dataset we compiled is unique; however the explicit
delineation of methodologies should allow other research groups to
replicate procedures. Additionally, phase lengths are influenced by
the spread of the data points. The majority of the vaccine
development dates (.50%) were collected after the year 2000
implying the spread of points is not equally distributed within the
dataset. This either suggests that the earlier years of the selected
timeframe are underrepresented, or that the actual quantity of
projects has increased over the years.
This paper provides a descriptive historical account of vaccine
development between 1998 and 2009, and does not have the
ambition to forecast any trends. Moreover we have not addressed
the numerous reasons that may lead to project termination, and do
not disregard the necessary legislative requirements in the
development of ethical, safe, effective, and high quality vaccines.
Figure 3. Combining the cumulative success rate with contextual factors. Combining the cumulative success rate with the contextual
factors of disease burden and size of investment (indicated by the size of the bubble).
doi:10.1371/journal.pone.0057755.g003
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